PORTAGE PHARMACEUTICALS
Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.
PORTAGE PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Address:
Toronto, Ontario, Canada
Country:
Canada
Status:
Active
Similar Organizations
BioSentinel Pharmaceuticals
BioSentinel develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Kato Pharmaceuticals
Kato Pharmaceuticals is a clinical stage Bio-pharmaceutical company dedicated to the development of novel therapies for pathologies.
Kyowa Pharmaceutical
Kyowa Pharmaceutical is developing and marketing a wide range of branded and generic formulations of drugs in Japan.
Tavec pharma
Tavec Pharmaceuticals is developing injectable therapies to treat cancers.
More informations about "Portage Pharmaceuticals"
Home - Portage Biotech
Portage Biotech (NASDAQ: PRTG) is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to achieve durable …See details»
Portage Pharmaceuticals - PitchBook
Portage Pharmaceuticals General Information Description. Developer of longevity-based therapies based in Tortola, British Virgin Islands. The company is involved in developing cell-permeable peptide (CPP) therapies to normalize …See details»
Portage Biotech - Crunchbase Company Profile
Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical "proof of concept" with an initial focus on unmet clinical needs. Following proof of concept, Portage will look to sell or license …See details»
Portage Biotech Divests Portage Pharmaceuticals Limited to …
Mar 4, 2021 Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno …See details»
about us - Portage Biotech
Portage Biotech aims to change this with a unique approach that drives the development of first-in-class immuno-oncology therapies for patients with cancer. ... Among our most notable projects is the early investment, formation and …See details»
Juvenescence acquires Portage Pharmaceuticals - 2021-03-04
Portage Pharmaceuticals Portage Pharmaceuticals is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression. Acquiring Organization: Juvenescence …See details»
Portage Biotech Inc - LinkedIn
Portage Biotech is clinical stage biopharmaceutical company driving the development of first-in-class immuno-oncology therapies to help more patients achieve durable treatment responses and a ...See details»
Annual Reports and Financial Statements
Furthermore, Portage is recognized for the excellence of its work by the organization Accreditation Canada with an honorable mention. Each year, the organization publishes a complete …See details»
Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from …
Mar 3, 2021 Portage Biotech divested three of it's businesses; Portage Pharmaceuticals Limited (PPL), including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd. In …See details»
Portage Biotech Divests Portage Pharmaceuticals Limited to …
Mar 3, 2021 Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario-- - Portage Biotech Inc. a clinical stage immuno-oncology company …See details»
Portage acquires majority interest in Biohaven Pharmaceutical …
Jan 6, 2014 Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical "proof of concept" with an initial focus on unmet clinical needs.See details»
Portage Pharmaceuticals - Crunchbase
Portage Pharmaceuticals is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression.See details»
Portage Biotech Inc. (PRTG) - Yahoo Finance Canada
See the company profile for Portage Biotech Inc. (PRTG) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Portage previews possible closure as it hunts for options
Apr 12, 2024 Portage reported having about $5 million in cash on hand as of the end of 2023. Portage Biotech is putting the clamps on existing work to save cash as it prioritizes a hunt for …See details»
our pipeline - Portage Biotech
* Portage Biotech has a 70% economic interest in PORT-4 (SAUG-1 and SAUG-2); and a 44% economic interest in PORT-5 (STIM1), which is being advanced in partnership with Stimunity. …See details»
Portage Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
Portage Pharmaceuticals is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression.See details»
Portage Biotech Inc. (PRTG) - Yahoo Finance Canada
Find the latest Portage Biotech Inc. (PRTG) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Portage Biotech Inc., a clinical stage …See details»
Portage Biotech Bolsters Pipeline with Acquisition of Four
Jul 6, 2022 Portage also announced that Robert Glassman, M.D., Ph.D., current EVP of Search and Evaluation at Enavate Sciences, and former independent director of Tarus Therapeutics, …See details»
NEWS RELEASE PORTAGE COMMENCES TRADING ON NASDAQ
Feb 25, 2021 PORTAGE BIOTECH INC. NEWS RELEASE PORTAGE COMMENCES TRADING ON NASDAQ - Trading of ordinary shares begins under the symbol “PRTG” – …See details»